Introduction
============

Astigmatism is a commonly occurring refractive error that leads to impaired visual acuity if uncorrected and is a risk factor for amblyopia \[[@r1]-[@r4]\]. The two major sources of refractive astigmatism in the human eye are the cornea and the crystalline lens. In emmetropic eyes, a low degree of with-the-rule (WTR) corneal astigmatism is typically compensated by a low degree of against-the-rule (ATR) lenticular astigmatism \[[@r5]\]. For individuals with higher levels of refractive astigmatism, corneal astigmatism is usually the major contributor, while lenticular astigmatism is within the normal range \[[@r6]\].

Studies in chicks have recently shown that the eye can compensate for experimentally induced astigmatism through the alteration of corneal curvature \[[@r7]\]. This suggests that the reduction in innate astigmatism seen during infancy in children occurs via active emmetropization \[[@r8]\]. Potential reasons why astigmatism still arises despite the presence of an emmetropization system include (a) astigmatism of too high a degree to be compensated within the juvenile period, (b) astigmatism outside the "operating range" of the emmetropization system, for example, producing a retinal image that is not detected as being caused by astigmatism or that arises at an age beyond that at which emmetropization normally acts, and (c) a failure of the emmetropization response \[[@r2]\].

Several lines of evidence support the role of genetics in the etiology of astigmatism. First, epidemiology studies have shown marked differences in the prevalence of astigmatism across ethnic groups, even after accounting for differences in spherical refractive error. For instance, 78% of native American Tohono O'odham children aged 0--8 have at least 1 diopter (D) of corneal astigmatism, and in Australian children aged 12, at least 1 D of corneal astigmatism was found in 19% of European individuals versus 50% of East Asian individuals \[[@r9],[@r10]\]. Second, corneal and refractive astigmatism have been reported as being moderately/highly heritable (heritability of 0.3--0.6) in twin studies \[[@r11],[@r12]\]. Third, a genetic segregation study in families with high-degree astigmatism found evidence of Mendelian inheritance \[[@r13]\]. Finally, genetic association studies have identified specific genetic variants associated with susceptibility to either refractive and/or corneal astigmatism \[[@r14]-[@r17]\]. Despite these latter studies, our understanding of the genetic contribution to astigmatism has lagged behind that of spherical refractive errors, for which dozens of genetic variants have been discovered \[[@r18]-[@r21]\].

Previously, the Consortium for Refractive Error and Myopia (CREAM) reported a genome-wide association study (GWAS) of refractive astigmatism that examined approximately two million genetic markers in 45,931 individuals \[[@r17]\]. Only a single marker reached genome-wide significance (rs1401327 in the *NRXN1* gene, p=3.92E−8). Reasoning that the paucity of genome-wide significant hits in the previous CREAM study may have been due to phenotypic uncertainty when studying refractive astigmatism that arose from the combination of both corneal and lenticular influence, CREAM has now undertaken a GWAS of corneal astigmatism. Fan et al. \[[@r16]\] performed a GWAS of corneal astigmatism using a discovery sample of 4,254 East Asian individuals and identified a genome-wide significant locus near the *PDGFRA* gene. In view of the success of the Fan et al. \[[@r16]\] study, the current analysis has adopted the same phenotype definition.

Methods
=======

The research study followed an analysis plan that was agreed upon by members of CREAM before starting work. This plan was designed to standardize methods across participating CREAM groups and to set timelines for the completion of specific tasks. All research groups known to CREAM with relevant genotype and phenotype data were invited to contribute to the study. Ethical approval for the study was obtained locally for each CREAM study group, and participants gave informed consent. The research was carried out in accordance with the tenets of the Declaration of Helsinki.

Study sample
------------

The demographics of the participating study groups are shown in [Table 1](#t1){ref-type="table"}. The participants comprised 22,250 European individuals from 14 studies and 9,120 Asian individuals from 8 studies. There were 5,470 European participants and 947 Asian participants aged \<25 years.

###### Subject demographics of participating CREAM study groups.

  **Study**       **Ancestry**   **N (cases/controls)**   **%Female**   **Age (years)**   **Corneal astigmatism (D)**   
  --------------- -------------- ------------------------ ------------- ----------------- ----------------------------- --------------
  ALSPAC          European       2279(985/1294)           53.1          15.5 (0.3)        0.683 (0.469--0.959)          0.000--5.680
  BMES            European       1238(720/518)            41.8          73.3 (7.6)        0.863 (0.565--1.295)          0.155--8.615
  EPIC            European       857(456/401)             58.5          68.7 (7.4)        0.780 (0.527--1.152)          0.075--3.997
  FITSA           European       127(62/65)               100           67.9 (3.1)        0.733 (0.530--1.033)          0.270--2.020
  GenerationR     European       2071(981/1090)           49.9          6.09 (0.4)        0.725 (0.480--0.995)          0.000--3.370
  GHS 1^1^        European       2398(1003/1395)          48.7          55.9 (10.8)       0.65 (0.400--0.950)           0.050--4.350
  GHS 2^1^        European       851(383/468)             50.9          55.1 (10.8)       0.65 (0.450--1.000)           0.050--3.800
  RAINE           European       1028(407/621)            50.9          20.0 (0.4)        0.649 (0.445--0.905)          0.280--2.440
  Rotterdam-I     European       5537(2064/3473)          59.3          69.5 (9.2)        0.601 (0.334--1.007)          0.000--9.663
  Rotterdam-II    European       1982(633/1349)           53.8          64.8 (8.0)        0.539 (0.294--0.884)          0.000--6.789
  Rotterdam-III   European       2925(1180/1745)          56.2          57 (6.9)          0.618 (0.356--1.019)          0.000--4.869
  OGP-A^2^        European       92(37/55)                44.6          16.0 (4.5)        0.682 (0.512--0.942)          0.185--3.070
  OGP-B^2^        European       446(181/265)             43.7          50.6 (15.4)       0.650 (0.430--0.970)          0.130--4.240
  TwinsUK         European       419(201/218)             92.7          64 (10.5)         0.729 (0.476--1.105)          0.000--5.432
  BES-610K^3^     Asian          553 (240/313)            65.6          62.1 (8.4)        0.666 (0.407--1.056)          0.000--3.620
  BES-OmniE^3^    Asian          469 (208/261)            60.1          64.7 (9.5)        0.676 (0.429--1.016)          0.000--5.082
  SCES-610K^3^    Asian          1745 (787/958)           48.7          57.6 (9.0)        0.703 (0.476--1.060)          0.109--5.868
  SCES-OmniE^3^   Asian          545 (257/288)            48.6          59.2 (8.8)        0.723 (0.470--1.065)          0.117--5.404
  SCORM           Asian          947 (768/179)            48.6          10.8 (0.8)        1.205 (0.851--1.624)          0.138--3.911
  SIMES           Asian          1778 (750/1028)          51.7          59.5 (10.8)       0.662 (0.432--1.016)          0.078--5.618
  SINDI           Asian          2261 (814/1447)          48.6          56.5 (9.1)        0.614 (0.411--0.912)          0.115--4.727
  STARS           Asian          822 (525/297)            50.0          38.5 (5.3)        1.000 (0.625--1.380)          0.125--3.875

^1^Association tests were undertaken separately for samples recruited in different waves. ^2^Association tests were undertaken separately for different age strata (stratum A, age \>3 and \<25 years; stratum B, age ≥25 years). ^3^Association tests were undertaken separately for samples genotyped on different platforms.

Phenotype definition
--------------------

Following Fan et al. \[[@r16]\], cases were defined as participants with corneal astigmatism \>0.75 D, and controls were defined as those with corneal astigmatism ≤0.75 D. Corneal astigmatism was averaged between the two eyes, except for participants with data available for only one eye. For the conversion of keratometry readings in millimeters to diopters, we used a conversion factor of 332 divided by the K-reading in mm \[[@r22]\].

Phenotyping, genotyping, and genetic imputation
-----------------------------------------------

Anterior corneal curvature was measured using keratometry (the keratometer used by each CREAM study group is listed in Appendix 1), and corneal astigmatism was calculated as the difference in curvature between the steepest and flattest meridians. Participants known to have keratoconus, corneal scarring, ocular surgery, or any corneal/ocular condition that would impair keratometry were excluded from the analysis. DNA samples were extracted from blood or saliva and genotyped on a high-density single nucleotide polymorphism (SNP) platform, as previously described \[[@r17]\]. Each CREAM study group imputed non-genotyped markers from an ancestry-matched reference panel from the 1000 Genomes Project \[[@r17]\] using IMPUTE2 \[[@r23]\] or Minimac \[[@r24]\]. Quality-control filtering was performed in accordance with standard GWAS practices \[[@r25]\]. In general, markers with per-study missingness \<0.95, minor allele frequency (MAF) \<0.05, or a Hardy--Weinberg disequilibrium p value \<1×10^−6^ were excluded, along with samples with per-study missingness \<0.95, extreme heterozygosity, sex mismatch, unaccounted for relatedness, or outlying ancestry \[[@r25]\]. Poorly imputed markers (IMPUTE2 info ≤0.5 or Minimac Rsq ≤0.5) were also excluded.

Genome-wide association studies and meta-analyses
-------------------------------------------------

Tests of association between corneal astigmatism case/control status and SNP genotype were performed genome-wide by each participating CREAM study group. The analysis was performed using PLINK \[[@r26]\] for marker genotypes coded 0, 1, or 2 or using mach2dat \[[@r24]\] or ProbABEL \[[@r27]\] for marker genotypes coded as imputed dosage on the scale 0--2. Age and sex were included as a continuous and a binary covariate, respectively. The first five major principal components were also included as continuous covariates if there was evidence of population stratification from Q-Q plots or the genomic control inflation factor (λ~GC~). For samples of related individuals, the analysis method took account of genetic background by treating this as a random effect in the analysis model. Tests of association were conducted separately for participants of European ancestry and participants of Asian ancestry and for younger (age \>3 and \<25) and older (age ≥25) participants.

Summary statistics from the participating CREAM study groups were submitted to a central site for meta-analysis. Using the approach implemented in easyQC \[[@r28]\], the summary statistics were evaluated by examining quality control plots and metrics, including effect allele frequency (EAF) plots, p value versus z-score (P-Z) plots, standard error versus sample size (SE-N) plots, effect size (odds ratio) distributions, and genomic control inflation factors. Queries were resolved by discussion with study groups analysts, and, where indicated, imputation or association testing was repeated.

Meta-analyses were performed separately for the four demographic strata---younger/older, European/Asian ancestry individuals. Fixed effects, standard error-weighted meta-analysis \[[@r29]\] was performed initially, followed by a random effects meta-analysis \[[@r30]\] for highly associated markers showing excessive between-study heterogeneity of I^2^\>0.5, where I^2^ is a measure of heterogeneity derived from Cochran's Q statistic \[[@r31]\]. A p value of 5×10^−8^ was adopted for declaring genome-wide significant association in the GWAS meta-analyses \[[@r32]\]. Regional association plots were created using LocusZoom \[[@r33]\]. Conditional analysis was performed on GWAS meta-analysis summary statistics using GCTA-COJO \[[@r34]\].

Gene-based tests and pathway analysis
-------------------------------------

Two gene-based tests, VEGAS2 \[[@r35]\] and MAGMA \[[@r36]\], were used to explore whether specific genes were enriched with strongly associated variants in the GWAS meta-analysis of older European individuals. Attention was restricted to the older European samples because gene-based testing relies on consistent patterns of linkage disequilibrium (LD) across genes, and the sample size was larger for the European meta-analysis compared to that for the Asian cohorts. Markers within 50 kb upstream and downstream of a gene were included in the gene-based tests, with the aim of detecting variants that altered the expression level of genes. The gene-based testing using MAGMA was repeated using an extended flanking region of 200 kb upstream and downstream of genes.

VEGAS2 \[[@r35]\] uses a fast approximation of a permutation-based test to determine whether genes are enriched for highly associated markers and makes use of LD information from an ancestry-matched reference panel to account for association signals shared by markers in LD. The test was implemented to analyze all markers in each gene. MAGMA \[[@r36]\] overcomes the low statistical power inherent when a gene contains many markers, some of which may be in strong LD, by first carrying out a principal components analysis (PCA) for the markers in each gene and then carrying out a per-gene linear regression analysis using the PCA eigenvectors as predictor variables. High statistical power is attained by limiting the regression to the major eigenvalues. Permutation-based p values are calculated to account for the use of a binary outcome as the dependent variable in the linear regression analysis \[[@r36]\].

Gene-set "pathway analysis" was also performed using MAGMA \[[@r36]\]. This was performed using a competitive approach whereby the test statistics for all genes within a gene set were combined to form a joint association statistic. This statistic was compared against that for all other genes not in that set while accounting for the number of SNPs within each gene, gene density, and differential sample size (unequal sample size contributing to each gene) \[[@r36]\]. Gene sets were defined using the Molecular Signatures Database (MSigDB) \[[@r37]\]. Gene definitions and their respective association signals for genes contributing to gene sets were taken from the MAGMA gene-based analyses with the aim of identifying potential biologic processes that may be influenced by these variants.

Shared genetic contribution to traits
-------------------------------------

LD score regression \[[@r38],[@r39]\] was used to quantify the degree of shared genetic contribution between corneal astigmatism and two related traits, refractive astigmatism and mean spherical equivalent refractive error. GWAS summary statistics for refractive astigmatism and for spherical equivalent refractive error were obtained from previous CREAM studies \[[@r17],[@r18]\]. LD score regression utilizes LD information from an ancestry-matched reference panel and requires large sample sizes; therefore, analyses were limited to European GWAS samples. Specifically, LD score regression was performed using the LDSC program \[[@r38],[@r39]\] for variants present in the HapMap3 CEU reference panel with MAF ≥0.05. The prevalence of corneal astigmatism (defined as an amount \>0.75 D) in the general population was taken as 42%, which was calculated as the average for the European ancestry population-based studies contributing to this meta-analysis. LD score regression remains valid when two traits are measured in overlapping samples \[[@r39]\], which was the case for these CREAM GWAS samples.

Results
=======

Meta-analysis of genome-wide association studies
------------------------------------------------

Meta-analyses were performed using a fixed effects model for approximately six million genetic variants (approximately 5,500,000 SNPs and 380,000 indels) in each of the four ancestry/age strata (younger European, older European, younger Asian, and older Asian). However, none of the markers had a p value below the pre-determined threshold of 5×10^−8^ used to declare genome-wide significance (Appendix 2, Appendix 3, Appendix 4, Appendix 5, Appendix 6, and Appendix 7). Therefore, to increase power, a meta-analysis was performed using data for all four ancestry/age strata, under the assumption that the genetic determinants of corneal astigmatism are consistent across ancestry groups and lifespan. This yielded 49 markers with p values \<5×10^−8^, all of which were located in a narrow interval on chromosome 4 close to the *PDGFRA* gene ([Figure 1](#f1){ref-type="fig"}, [Figure 2](#f2){ref-type="fig"}, and [Figure 3](#f3){ref-type="fig"}). This locus has previously been identified in GWAS analyses for corneal astigmatism \[[@r16]\], refractive astigmatism \[[@r17]\], and corneal curvature \[[@r15],[@r40],[@r41]\]. [Table 2](#t2){ref-type="table"} lists the most strongly associated marker in each region showing suggestive association, defined as a region with at least one marker with p\<1×10^−5^. Both the European and Asian meta-analyses contributed to the association signal at the *PDGFRA* locus; the most strongly associated marker, rs7673984, had an effect size (odds ratio) of OR=1.15 (95% CI:1.07--1.24; p=1.76×10^−4^) in Asians, OR=1.11 (95% CI:1.06--1.16; p=5.64×10^−6^) in Europeans, and OR=1.12 (95% CI:1.08--1.16; p=5.55×10^−9^) in the meta-analysis of Asians and Europeans. The association of rs7673984 in the individual cohorts examined is summarized in [Figure 4](#f4){ref-type="fig"}. Conditional analysis using GCTA-COJO yielded no additional association signals at the *PDGRFA* locus independent of rs7673984.
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###### Most strongly associated marker in each region in the GWAS meta-analysis of all samples (Europeans and Asians of all ages combined).

  **SNP**       **Chr**   **Pos**       **Effect allele**   **Other allele**   **EAF**   **OR (95%CI)**      **P value**   **Nearest gene**
  ------------- --------- ------------- ------------------- ------------------ --------- ------------------- ------------- ------------------
  rs7673984     4         55,088,761    T                   C                  0.22      1.12 (1.08--1.16)   5.55×10^−9^   *PDGFRA*
  rs34751092    4         24,129,037    A                   G                  0.28      1.09 (1.05--1.13)   6.07×10^−7^   *PPARGC1A*
  rs630203      5         141,444,269   T                   G                  0.74      0.92 (0.88--0.95)   8.83×10^−7^   *MRPL11P2*
  rs75607298    8         128,611,496   A                   G                  0.72      1.14 (1.08--1.21)   2.28×10^−6^   *CASC11*
  rs62401199    6         43,813,341    T                   C                  0.14      1.15 (1.09--1.22)   3.29×10^−6^   *LINC01512*
  rs753992      11        47,349,846    A                   G                  0.29      0.91 (0.87--0.95)   3.48×10^−6^   *MADD*
  rs3214101     11        114,009,408   A                   T                  0.68      1.08 (1.05--1.12)   3.75×10^−6^   *ZBTB16*
  rs10985068    9         123,629,724   C                   G                  0.12      1.13 (1.07--1.19)   5.87×10^−6^   *PHF19*
  rs62128379    2         26,960,055    T                   C                  0.85      1.13 (1.07--1.19)   6.00×10^−6^   *KCNK3*
  rs9939114     16        84,023,972    A                   G                  0.05      0.54 (0.41--0.70)   6.01×10^−6^   *NECAB2*
  rs60083876    7         34,228,819    A                   T                  0.95      1.31 (1.17--1.48)   6.53×10^−6^   *BMPER*
  rs859362      1         175,495,090   T                   C                  0.19      1.10 (1.05--1.15)   7.14×10^−6^   *TNR*
  rs11775037    8         108,317,615   A                   G                  0.20      1.10 (1.05--1.14)   7.31×10^−6^   *ANGPT1*
  rs7036824     9         96,149,894    T                   C                  0.94      0.83 (0.77--0.90)   8.78×10^−6^   *C9orf129*
  rs142168171   7         71,253,651    I                   R                  0.09      1.37 (1.19--1.57)   9.14×10^−6^   *CALN1*
  rs7278671     21        41,047,876    A                   G                  0.51      0.93 (0.90--0.96)   9.31×10^−6^   *B3GALT5*
  rs191640722   1         119,264,997   C                   G                  0.09      0.87 (0.82--0.93)   9.53×10^−6^   *LOC100421281*
  rs36107906    2         44,162,800    D                   R                  0.29      1.09 (1.05--1.13)   9.61×10^−6^   *LRPPRC*
  rs4896367     6         138,807,281   T                   C                  0.72      1.09 (1.05--1.14)   9.75×10^−6^   *NHSL1*
  rs35587414    1         153,174,958   T                   C                  0.15      1.13 (1.07--1.20)   9.79×10^−6^   *LELP1*

EAF=effect allele frequency, OR=odds ratio.
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Gene-based analyses
-------------------

To explore whether specific genes were enriched for markers with low p values in the GWAS meta-analysis, we performed gene-based tests using VEGAS2 \[[@r35]\] and MAGMA \[[@r36]\]. These programs use different approaches to test for such enrichment (see *Methods*). Due to the requirement for an ancestry-matched reference panel, analyses were conducted using the results of a GWAS meta-analysis of European samples of all ages (however, similar results were obtained when attention was restricted to the meta-analysis of older Europeans). The 10 most strongly associated genes from the VEGAS2 and MAGMA analyses are shown in Appendix 8 and Appendix 9. There was a high degree of overlap between the results of the two programs, with the genes *ACP2*, *CLDN7*, *ELP5*, and *CTDNEP1* showing the strongest association in both analyses (Appendix 8 and Appendix 9). In the MAGMA gene-based test, these four genes and *TNFAIP8L3* achieved p\<0.05 after stringent Bonferroni correction, whereas this was not the case for VEGAS (Appendix 8 and Appendix 9). A further exploratory gene-based analysis that included markers up to 200 kb upstream or downstream of each gene---an approach that has been successful for certain traits \[[@r42]\]---failed to identify any additional genes associated with corneal astigmatism.

Pathway analysis
----------------

As biologic processes tend to involve multiple genes, a gene-set analysis was performed with MAGMA \[[@r36]\] using the gene-based analysis results for the European samples. Gene-set analyses seek to identify potential biologic mechanisms enriched for genes with markers attaining low p values in the GWAS meta-analysis. However, no gene sets were identified as demonstrating a greater level of association with corneal astigmatism than would be expected by chance (when flanking regions of either ±50 kb or ±200 kb upstream or downstream of genes were tested).

SNP heritability and genetic correlation between traits
-------------------------------------------------------

LD score regression was used to quantify the heritability explained by commonly occurring genetic variants ("SNP heritability") and the degree of genetic sharing between corneal astigmatism and two related traits, refractive astigmatism and spherical equivalent refractive error ([Table 3](#t3){ref-type="table"} and [Table 4](#t4){ref-type="table"}). The SNP heritability (h^2^) estimates for corneal and refractive astigmatism (\~5% and \~1%, respectively) were lower than for the spherical equivalent (\~23%); indeed, the SNP heritability estimates for corneal and refractive astigmatism were not significantly different from zero. The genetic correlation estimates also had high standard errors and therefore yielded very imprecise estimates ([Table 4](#t4){ref-type="table"}). These hinted at a high genetic correlation between corneal astigmatism and the spherical equivalent; however, in view of the low SNP heritability estimate for the astigmatism traits, these findings imply that much larger sample sizes and/or a more homogeneous population sample is needed to obtain robust findings.

###### SNP-heritability estimated using LD Score Regression (Europeans only).

  **Trait**                   **No. of Markers**   **SNP-heritability (SE)**   **P value**
  --------------------------- -------------------- --------------------------- --------------
  Corneal Astigmatism         1,024,525            0.0555 (0.0381)             0.15
  Refractive Astigmatism      1,056,658            0.0136 (0.0218)             0.53
  Mean Spherical Equivalent   1,056,658            0.2326 (0.0175)             2.60×10^−40^

###### Genetic correlations between pairs of refractive error traits in samples of European ancestry from the CREAM consortium (using LD Score Regression).

  **Trait Pairs**   **No. of Markers**   **Genetic Correlation (SE)**   **P value**
  ----------------- -------------------- ------------------------------ -------------
  RA and CA         934,512              0.2327 (0.703)                 0.7406
  MSE and CA        1,024,525            −0.0238 (0.1599)               0.8815
  RA and MSE        1,056,658            0.7732 (0.6504)                0.2345

RA=refractive astigmatism, CA=corneal astigmatism, MSE=mean spherical equivalent. P values refer to likelihood of non-zero correlation between traits.

Discussion
==========

This GWAS for corneal astigmatism in a combined sample of Europeans and Asians identified a single genome-wide significant locus in the promoter region of the *PDGFRA* gene, replicating the previous discovery of this corneal astigmatism locus by Fan et al. \[[@r16]\] in a predominantly Asian sample. Therefore, despite a fourfold increase in sample size (n=31,370 versus n=7,719) compared to the only previous GWAS meta-analysis for corneal astigmatism \[[@r16]\], the standard, single-marker GWAS analysis performed here did not identify any new loci. GWAS analyses for spherical equivalent and other morphological traits in equivalently sized samples have identified dozens of independent risk loci \[[@r18],[@r19]\]. This paucity of GWAS loci for corneal astigmatism mirrors that observed in a previous large-scale GWAS for refractive astigmatism \[[@r17]\]. Our LD score regression-based SNP heritability estimates for corneal astigmatism (h^2^ \~5%) and refractive astigmatism (h^2^ \~1%)---the first ever estimates for these traits---were also much lower than those for the spherical equivalent (h^2^ \~23%), suggesting that common, additively acting SNPs make a relatively minor contribution to the development of astigmatism. In the study by Fan et al. \[[@r16]\] that originally identified the association between SNPs close to the *PDGFRA* gene and corneal astigmatism, the authors speculated that the underlying causal mechanism was common to populations of diverse ancestry and not specifically to those of Asian origin. This was based on the knowledge that their GWAS included individuals of Indian ancestry, who are more closely genetically related to Europeans than East Asians \[[@r16]\]. Our findings support this theory.

The association between *PDGFRA* SNPs and corneal astigmatism has been replicated in a previous study of Europeans (n=1968) but not in another smaller study (n=1013) \[[@r41],[@r43]\]. Variants at this locus were not associated with refractive astigmatism in GWAS meta-analyses of n=45,287 participants \[[@r17]\] yet were associated with corneal curvature in an Asian sample \[[@r15]\] and with both corneal curvature and axial length (but not refractive error) in a European sample \[[@r41]\]. This complex series of findings suggests a role for *PDGRFA* in the regulation of eye size and corneal astigmatism; however, the underlying mechanism of action remains uncertain.

In contrast to the single-marker analyses, gene-based analysis did provide new insight into the genetic basis of corneal astigmatism, implicating the genes *ACP2*, *CLDN7*, *CTDNEP1*, *ELP5*, and *TNFAIP8L3*. Three of these five genes---*CLDN7*, *CTDNEP1*, and *ELP5*---are tightly clustered on chromosome 11, with their respective (gene-based) association signals sharing many variants in common. Therefore, a parsimonious interpretation is that only one of the genes has a causal association with astigmatism and that the other two genes are false-positive associations detected due to the signal from the causal gene. Of the three genes, *CLDN7*, which encodes the claudin-7 membrane protein \[[@r44]\], appears to be the most biologically plausible candidate. Claudins are responsible for tight junction formation and function \[[@r45]\], with claudin-7 being the subtype present in human corneal epithelium and endothelium \[[@r46]\]. Currently, how claudin-7 may contribute to the development of corneal astigmatism is unclear. The acid phosphatase 2, lysosomal gene (*ACP2*) is located on chromosome 17 and codes for the beta subunit of the degradative enzyme, lysosomal acid phosphatase (LAP). Interestingly, LAP activity is enhanced in keratoconic corneas \[[@r47],[@r48]\]. The *TNFAIP8L3* gene located on chromosome 15 codes for TNF alpha-induced protein 8 like 3, which is preferentially expressed in secretory epithelial cells \[[@r49]\]. *TNFAIP8L3* is implicated as a negative regulator of inflammation (and carcinogenesis) through its role in TNFα and phospholipid signaling. Based on this evidence, the *CLDN7*, *ACP2*, and *TNFAIP8L3* genes are promising susceptibility genes for corneal astigmatism. It is important to note that while the statistical support for the above three genes was much stronger in the MAGMA analysis than in the VEGAS2 analysis, the two software programs similarly ranked the most strongly associated genes. This commonality between the MAGMA and VEGAS2 results provides greater confidence that the findings are robust than would be the case for findings identified using either software program alone, as the statistical models and hypothesis tests used by the two programs differ, especially regarding the adjustment for variants in LD.

The strengths of this investigation are that data from multiple population samples were combined and meta-analyzed and that gene-based and pathway-based follow-up analyses were undertaken to leverage new biologic insights into the genetics of astigmatism. The weaknesses were that although the samples included both European and Asian ancestry individuals, trans-ethnic meta-analysis \[[@r50]\] was not performed due to the small size of the Asian sample compared to the European sample and that the age spectrum of the participants was very broad. The latter point is an important consideration because astigmatism does not remain constant during life, with changes in both magnitude and orientation occurring with age \[[@r1]\]. For example, in childhood, astigmatism tends to be WTR, whereas in older adults this orientation typically changes to ATR. Our study design sought to overcome some of this variation by considering only the magnitude of corneal astigmatism (i.e., no consideration of astigmatism axis) and by using a case-control classification scheme, with the aim of reducing the impact of the subtle changes in astigmatism that commonly occur with age.

In conclusion, this GWAS meta-analysis for corneal astigmatism replicated the discovery of a genome-wide significant locus near the *PDGFRA* gene \[[@r16]\] and provided strong evidence that this locus is important in both Asians and Europeans ([Figure 4](#f4){ref-type="fig"}). Three novel candidate genes, *CLDN7*, *ACP2*, and *TNFAIP8L3*, were identified using gene-based analyses that leveraged data from across genomic regions rather than from examining one genetic marker at a time. These novel genes warrant further investigation to understand their role in the pathogenesis of corneal astigmatism. Finally, exploiting the recently introduced LD score regression technique, we estimated the SNP heritability of corneal astigmatism (and refractive astigmatism) to be much lower than that for spherical equivalent refractive error ([Table 3](#t3){ref-type="table"}) \[[@r51]\]. This implies that astigmatism must be under greater influence of rare genetic variants or environmental risk factors than spherical equivalent or that the common genetic variants that contribute to astigmatism have non-additive effects.

**ALSPAC**. The Avon Longitudinal Study of Parents and Children (ALSPAC) team and authors are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council and Wellcome Trust (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corportation of America) using support from 23andMe. This publication is the work of the authors and JAG and CW will serve as guarantors for the contents of this paper. This research was specifically funded by NIHR Senior Research Fellowship SRF-2015--08--005 (CW) and a Wellcome Trust ISSF Populations Pilot Award (grant 508353/509506). Ethical approval for the ALSPAC study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Please note that the ALSPAC study website contains details of all the data that is available through a fully searchable data dictionary: http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/. ALSPAC children with available genotype data and corneal curvature phenotype information formed the GWAS sample ([Table 1](#t1){ref-type="table"}). A description of the ALSPAC study cohort is available \[[@r52]\]. **BES.** The Beijing Eye Study (BES) was supported by National Natural Science Foundation of China (grant \# 81770890). This publication is the work of the authors and YXW and JBJ will serve as guarantors for the contents of this paper. The study was approved by the Medical Ethics Committee of the Beijing Tongren Hospital. A description of the BES study cohort is available \[[@r53]\]. **BMES**. The Blue Mountains Eye Study (BMES) acknowledge funding from the National Health and Medical Research Council of Australia (NHMRC) Senior Research Fellowship 1138585 (PNB). The Centre for Eye Research Australia (CERA) receives Operational Infrastructure Support from the Victorian Government. Details of the BMES cohort have been published previously \[[@r54]\]. **EPIC.** The European Prospective Investigation of Cancer (EPIC)-Norfolk infrastructure and core functions are supported by grants from the Medical Research Council (G1000143) and Cancer Research UK (C864/A14136). The clinic for the third health examination was funded by Research into Aging (262). Mr Khawaja was a Wellcome Trust Clinical Research Fellow at the time of analysis. The EPIC-Norfolk Eye Study was performed following the principles of the Declaration of Helsinki and the Research Governance Framework for Health and Social Care. The study was approved by the Norfolk Local Research Ethics Committee (05/Q0101/191) and East Norfolk & Waveney NHS Research Governance Committee (2005EC07L). All participants gave written, informed consent. A description of the EPIC study cohort is available \[[@r55]\]. **FITSA.** Finnish Twin Study on Aging (FITSA) is a study of genetic and environmental effects on the disablement process in older female twins. The study cohort of 13,888 adult twin pairs started in 1975. Altogether 103 MZ and 114 DZ twin pairs (424 individuals, all women of European ancestry) aged 63--76 years living in Finland took part in multiple laboratory examinations in 2000 and 2003, and responded in questionnaires in 2011. Before the examinations, the subjects provided a written informed consent according to the Declaration of Helsinki. The study protocol was approved by the ethics committee of the Central Hospital District of Central Finland. FITSA was supported by ENGAGE (FP7-HEALTH-F4--2007, 201,413); European Union through the GENOMEUTWIN project (QLG2-CT-2002--01254); the Academy of Finland Center of Excellence in Complex Disease Genetics (213506, 129680); the Academy of Finland Aging Programme; and the Finnish Ministry of Culture and Education and University of Jyväskylä, Silmäsäätiö Foundation and Evald & Hilda Nissi Foundation. For FITSA the contributions of Emmi Tikkanen, Samuli Ripatti, Markku Kauppinen, Taina Rantanen and Jaakko Kaprio are acknowledged. A description of the FITSA cohort has been published \[[@r56]\]. **Generation R.** The Generation R study is conducted by the Erasmus Medical Centre in close collaboration with the School of Law and Faculty of Social Sciences of the Erasmus University Rotterdam, the Municipal Health Service Rotterdam, the Rotterdam Homecare Foundation, and the Stichting Trombosedienst & Artsenlaboratorium Rijnmond (Star-MDC), Rotterdam. We gratefully acknowledge the contribution of the children and parents, as well as the participating general practitioners, hospitals, midwives, and pharmacies in Rotterdam. The Generation R study is made possible by financial support from the Erasmus Medical Centre, Rotterdam; the Netherlands Organisation for Scientific Research (NWO); the Netherlands Organisation for Health Research and Development (ZonMw); the Dutch Ministry of Education, Culture and Science; the Dutch Ministry of Health, Welfare, and Sports; the European Commission (DG XII); and UitZicht (Grant 2013--24). The study protocol was approved by the Medical Ethical Committee of the Erasmus Medical Centre, Rotterdam (MEC 217.595/2002/20), and written informed consent was obtained from all participants. Research was conducted according to the declaration of Helsinki. A description of the Generation R study has been published \[[@r57]\]. **Gutenberg Health Study (GHS 1 and GHS 2).** The Gutenberg Health Study is a population-based, prospective, observational cohort study in mid-western Germany that includes consecutive follow-ups every five years. The primary study aim is to evaluate and improve cardiovascular risk stratification and the general health status of the population. The baseline examination included a total of 15,010 participants aged 35 to 74 years and took place from 2007 to 2012. The participants were randomly drawn and equally stratified for sex, residence (urban or rural) and for each decade of age. Exclusion criteria were the following: insufficient knowledge of German and physical or mental inability to participate in the examinations in the study center. The study protocol and study documents were approved by the local ethics committee of the Medical Chamber of Rhineland-Palatinate, Germany (reference no. 837.020.07; original vote: 22.3.2007, latest update: 20.10.2015). According to the tenets of the Declaration of Helsinki, written informed consent was obtained from all participants before their entry into the study. The Gutenberg Health Study is funded through the government of Rhineland-Palatinate ("Stiftung Rheinland-Pfalz für Innovation," contract AZ 961--386261/733), the research programs "Wissen schafft Zukunft" and "Center for Translational Vascular Biology (CTVB)" of the Johannes Gutenberg-University of Mainz, the National Genome Network "NGFNplus" by the Federal Ministry of Education and Research, Germany (A301GS0833) and its contracts with Boehringer Ingelheim and PHILIPS Medical Systems. We thank all study participants for their willingness to provide data for this research project and we are indebted to all coworkers for their enthusiastic commitment. A description of the ophthalmic arm of the GHS has been published \[[@r58]\]. **OGP.** The Ogliastra Genetic Park (OGP) study authors would like to express their gratitude to all the study participants for their contributions, to the municipal administrations for their economic and logistic support and, to the whole OGP team, which includes interviewers, computer and laboratory technicians, research scientists, physicians and nurses. This research was supported by grant from the Italian Ministry of Education, University and Research (MIUR) no: 5571/DSPAR/2002. The research protocol of the study was approved by the institutional review board of the Italian Ministry of Education, University and Research. It adheres to the tenets of the declaration of Helsinki, furthermore written informed consent was obtained from all participants. A description of the OGP study cohort has been published \[[@r59]\]. **RAINE** (Western Australian Pregnancy Cohort). We are grateful to all the study participants. We also thank the Raine Study and Lions Eye Institute (LEI) research staff for cohort coordination and data collection. The core management of the Raine Study is funded by The University of Western Australia (UWA), The Telethon Institute for Child Health Research, Raine Medical Research Foundation, UWA Faculty of Medicine, Dentistry and Health Sciences, Women's and Infant's Research Foundation and Curtin University. Genotyping was funded by Australian National Health and Medical Research Council (NHMRC) project grant 1021105. Support for the REHS was provided by LEI, the Australian Foundation for the Prevention of Blindness and ORIA. SY is supported by NHMRC CJ Martin Early Career Fellowship (\#1111437). A description of the RAINE Eye Health Study study cohort is available \[[@r60]\]. **Rotterdam Study (RS1, RS2, RS3).** The Rotterdam Study is a prospective population-based cohort study in the elderly living in Ommoord, a suburb of Rotterdam, the Netherlands. In brief, the Rotterdam Study consists of 3 independent cohorts: RS1, RS2, and RS3. For the current analysis, 5,328 residents aged 55 years and older were included from RS1, 2,009 participants aged 55 and older from RS2, and 1,970 aged 45 and older from RS 3. 99% of subjects were of European ancestry. Participants underwent multiple physical examinations with regular intervals from 1991 to present, including a non-dilated automated measurement of refractive error using a Topcon RM-A2000 autorefractor. All measurements in RS-1--3 were conducted after the Medical Ethics Committee of the Erasmus University had approved the study protocols and all participants had given a written informed consent in accordance with the Declaration of Helsinki. The Rotterdam Study was supported by the Dutch governmental Innovational Research Incentives Scheme Grant (VICI 91815655); Horizon2020 ERC Consolidator Grant (648268); Erasmus Medical Center and Erasmus University, Rotterdam, The Netherlands; Netherlands Organization for Health Research and Development (ZonMw); UitZicht; the Research Institute for Diseases in the Elderly; the Ministry of Education, Culture and Science; the Ministry for Health, Welfare and Sports; the European Commission (DG XII); the Municipality of Rotterdam; the Netherlands Genomics Initiative/NWO; Center for Medical Systems Biology of NGI; Lijf en Leven; Henkes Stichting; Landelijke Stichting voor Blinden en Slechtzienden; Oogfonds; MaculaFonds. We acknowledge Ada Hooghart, Corina Brussee, Riet Bernaerts-Biskop, Patricia van Hilten, Pascal Arp, Jeanette Vergeer, Marijn Verkerk; Sander Bervoets for their valuable contributions. A description of the Rotterdam study has been published \[[@r61]\]. **SCES, SIMES and SINDI.** The Singapore Chinese Eye Study (SCES), Singapore Malay Eye Study (SiMES) and Singapore Indian Eye Study (SINDI) were supported by the National Medical Research Council (NMRC), Singapore (grants 0796/2003, 1176/2008, 1149/2008, STaR/0003/2008, 1249/2010, CG/SERI/2010, CIRG/1371/2013, and CIRG/1417/2015), and Biomedical Research Council, Singapore (08/1/35/19/550 and 09/1/35/19/616). Ching-Yu Cheng is supported by an award from NMRC (CSA/033/2012). Descriptions of the SCES, SIMES and SINDI cohorts have been published \[[@r62]-[@r64]\]. **SCORM.** The Singapore Cohort Study of the Risk Factors for Myopia (SCORM) was supported by the Biomedical Research Council (BMRC) 06/1/21/19/466. A description of the SCORM cohort has been published \[[@r65]\]. **STARS.** The Singaporean Chinese in the Strabismus, Amblyopia, and Refractive Error Study (STARS) was supported by National Medical Research Council (NMRC), Singapore (grants 1176/2008). A description of the STARS cohort has been published \[[@r66]\]. **TwinsUK.** The TwinsUK adult twin registry based at St. Thomas' Hospital in London is a volunteer cohort of over 10,000 twins from the general population. Twins largely volunteered unaware of the eye studies, gave fully informed consent under a protocol reviewed by the St. Thomas' Hospital Local Research Ethics Committee. TwinsUK is funded by the Wellcome Trust and the European Community\'s Seventh Framework Programme (FP7/2007--2013). The study also receives support from the National Institute for Health Research Clinical Research Facility at Guy\'s and St. Thomas\' National Health Service Foundation Trust and National Institute for Health Research Biomedical Research Centre at Guy\'s and St. Thomas\' National Health Service Foundation Trust and King\'s College London. Keratometry was obtained using the VX-120 ocular diagnostic device (Visionix®, Luneau Technology Group). A description of the TwinsUK study cohort is available \[[@r67]\]. **CREAM Meta-analyses.** This work was supported in part by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health.
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Manhattan plots for the separate ancestry/age strata fixed effects meta-analyses. Y-axes show negative log~10~ p-values and X-axes show genomic position. Red line corresponds to P = 5 x 10^-8^, blue line corresponds to P = 1 x 10^-5^. Panel A, European ancestry, aged \>25 years; B, European ancestry, aged \<25 years; C, Asian ancestry, aged \>25 years; D, Asian ancestry, aged \<25 years. To access the data, click or select the words "[Appendix 2](http://www.molvis.org/molvis/v24/appendices/mv-v24-127-app-2.docx)"

Y-axes show observed negative log~10~ p-values and X-axes show expected negative log~10~ p-values according to the null hypothesis of no genetic association. Red line is the line of unity (y = x). Panel **A**, European ancestry, aged \>25 years; **B**, European ancestry, aged \<25 years; **C**, Asian ancestry, aged \>25 years; **D**, Asian ancestry, aged \<25 years. To access the data, click or select the words "[Appendix 3](http://www.molvis.org/molvis/v24/appendices/mv-v24-127-app-3.docx)"
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Start and stop positions listed include ±50kb buffers. nSNPs: number of variants included in gene region. Test Statistic: gene-based χ2 test statistic to nSNPs degrees of freedom. P-value: obtained from Test Statistic and adjusting for LD between variants. FDR: false discovery rate (likelihood of gene association being a false positive result). Top SNP: variant within gene locus with strongest association signal from previous SNP-based association test. Genes shown in bold were also identified with MAGMA (Appendix 9). To access the data, click or select the words "[Appendix 8](http://www.molvis.org/molvis/v24/appendices/mv-v24-127-app-8.docx)"

Start and stop positions listed include ±50kb buffers. nSNPs: number of variants included in gene region. Z Statistic: gene-based test statistic. P-value: obtained from *Z Statistic* under the assumption of a normally distributed model. FDR: false discovery rate (likelihood of gene association being a false positive result). Genes shown in bold were also identified with VEGAS2 (Appendix 8). To access the data, click or select the words "[Appendix 9](http://www.molvis.org/molvis/v24/appendices/mv-v24-127-app-9.docx)"
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